Vericel Reports Strong Q4 & Full-Year 2025 Results, Issues Positive 2026 Guidance

summarizeSummary

Vericel Corporation announced robust financial results for Q4 and full-year 2025, exceeding prior year performance across key metrics, and provided optimistic revenue and profit guidance for 2026.

check_boxKey Events

• Strong Q4 2025 Performance

  Total net revenue increased 23% to $92.9 million, with MACI revenue also up 23%. Net income rose 17% to $23.2 million, and adjusted EBITDA grew 25% to $37.3 million.

• Robust Full-Year 2025 Growth

  Total net revenue reached $276.3 million, a 16% increase year-over-year. Net income surged 59% to $16.5 million, and adjusted EBITDA increased 33% to $70.9 million.

• Positive 2026 Financial Guidance

  The company projects total revenue between $316 million and $326 million, and MACI revenue between $280 million and $286 million, indicating continued strong growth.

• Operational Milestones Achieved

  Vericel achieved record MACI implants and biopsies in Q4, completed its MACI sales force expansion, and initiated a new MACI clinical study (MACI Ankle™ MASCOT).

auto_awesomeAnalysis

Vericel Corporation delivered impressive growth in both the fourth quarter and the full fiscal year 2025, driven by strong MACI revenue. The significant increase in net income and adjusted EBITDA demonstrates improved profitability. The 2026 financial guidance projects continued double-digit revenue growth and stable margins, indicating a positive outlook for the company's core businesses and operational efficiency. The completion of the MACI sales force expansion and progress on new facilities and clinical studies further support future growth.